Inhibitory Effect of Biotransformed- Fucoidan on the Differentiation of Osteoclasts Induced by Receptor for Activation of Nuclear Factor-κB Ligand
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Bone homeostasis is regulated by constant remodeling through osteogenesis by osteoblasts and osteolysis by osteoclasts and osteoporosis can be provoked when this balance is broken. Present pharmaceutical treatments for osteoporosis have harmful side effects and thus, our goal was to develop therapeutics from intrisincally safe natural products. Fucoidan is a polysaccharide extracted from many species of brown seaweed, with valuable pharmaceutical activities. To intensify the effect of fucoidan on bone homeostasis, we hydrolyzed fucoidan using AMG, Pectinex and Viscozyme. Of these, fucoidan biotransformed by Pectinex (Fu/Pec) powerfully inhibited the induction of tartrate-resistant acid phosphatase (TRAP) activity in osteoclasts differentiated from bone marrow macrophages (BMMs) by the receptor for activation of nuclear factor-κB ligand (RANKL). To investigate potential of lower molecular weight fucoidan it was separated into >300 kDa, 50-300 kDa, and <50 kDa Fu/Pec fractions by ultrafiltration system. The effects of these fractions on TRAP and alkaline phosphatase (ALP) activities were then examined in differentiated osteoclasts and MC3T3-E1 osteoblasts, respectively. Interestingly, 50-300 kDa Fu/Pec suppressed RANKL-induced osteoclasts differentiation from BMMs but did not synergistically enhance osteoblasts differentiation induced by osteogenic agents. In addition, this fraction inhibited the expressions of NFATc1, TRAP, OSCAR, and RANK, which are all key transcriptional factors involved in osteoclast differentiation, and those of Src, c-Fos and Mitf, as determined by RT-PCR. In conclusion, enzymatically low-molecularized 50-300 kDa Fu/Pec suppressed TRAP by downregulating RANKLrelated signaling, contributing to the inhibition of osteoclasts differentiation, and represented a potential means of inducing bone remodeling in the background of osteoporosis.
Abstract
Bone homeostasis is regulated by constant remodeling through osteogenesis by osteoblasts and osteolysis by osteoclasts and osteoporosis can be provoked when this balance is broken. Present pharmaceutical treatments for osteoporosis have harmful side effects and thus, our goal was to develop therapeutics from intrisincally safe natural products. Fucoidan is a polysaccharide extracted from many species of brown seaweed, with valuable pharmaceutical activities. To intensify the effect of fucoidan on bone homeostasis, we hydrolyzed fucoidan using AMG, Pectinex and Viscozyme. Of these, fucoidan biotransformed by Pectinex (Fu/Pec) powerfully inhibited the induction of tartrate-resistant acid phosphatase (TRAP) activity in osteoclasts differentiated from bone marrow macrophages (BMMs) by the receptor for activation of nuclear factor-κB ligand (RANKL). To investigate potential of lower molecular weight fucoidan it was separated into >300 kDa, 50-300 kDa, and <50 kDa Fu/Pec fractions by ultrafiltration system. The effects of these fractions on TRAP and alkaline phosphatase (ALP) activities were then examined in differentiated osteoclasts and MC3T3-E1 osteoblasts, respectively. Interestingly, 50-300 kDa Fu/Pec suppressed RANKL-induced osteoclasts differentiation from BMMs but did not synergistically enhance osteoblasts differentiation induced by osteogenic agents. In addition, this fraction inhibited the expressions of NFATc1, TRAP, OSCAR, and RANK, which are all key transcriptional factors involved in osteoclast differentiation, and those of Src, c-Fos and Mitf, as determined by RT-PCR. In conclusion, enzymatically low-molecularized 50-300 kDa Fu/Pec suppressed TRAP by downregulating RANKLrelated signaling, contributing to the inhibition of osteoclasts differentiation, and represented a potential means of inducing bone remodeling in the background of osteoporosis.
참고문헌 (43)
- Confavreux CB, "Bone : from a reservoir of minerals to a regulator of energy metabolism", Kidney Int, 79121, pp.S14~19 (2011)
- Abdul Alim Al‐Bari, "Current advances in regulation of bone homeostasis", FASEB BioAdvances, 2(11), pp.668~679 (2020), Wiley[DOI]
- Kim JM, "Osteoblast-osteoclast communication and bone homeostasis", Cells, 9, pp.2073~ (2020)
- 김정하, "Signaling Pathways in Osteoclast Differentiation", 전남의대학술지, 52(1), pp.12~17 (2016), 의과학연구소
- Takayanagi H, "Induction and activation of the transcription factor NFATc1(NFAT2)integrate RANKL signaling in terminal differentiation of osteoclasts", Dev. Cell, 3, pp.889~901 (2002)
- Pennanen P, "Signaling pathways in human osteoclasts differentiation : ERK1", 2 as a key player, 2021, pp.48, 1243~1254
- Phimphilai M, "BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype", J. Bone Miner. Res, 21, pp.637~646 (2006)
- Amarasekara DS, "Regulation of osteoblast differentiation by cytokine networks", Int. J. Mol. Sci, 22, pp.2851~ (2021)
- Golub EE, "The role of alkaline phosphatase in mineralization", Curr. Opin. Orthop, 18, pp.444~448 (2007)
- Lotz EM, "Bisphosphonates inhibit surface-mediated osteogenesis", J. Biomed. Mater. Res. A, 108, pp.1774~1786 (2020)
- Levin VA, "Estrogen therapy for osteoporosis in the modern era", Osteoporos. Int, 9, pp.1049~1055 (2018)
- 오승훈, "Current Medical Therapies for Osteoporosis and Its Alternative Treatments Using Natural Products", 생명과학회지, 25(1), pp.113~120 (2015), 한국생명과학회
- Xi Zheng, "Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling", Journal of Medicinal Food, 19(1), pp.1~14 (2016), 한국식품영양과학회[DOI]
- Martiniakova M, "Pharmacological agents and natural compounds : available treatments for osteoporosis", J. Physiol. Pharmacol, 71, pp.307~320 (2020)
- Kim YW, "Fucoidan, a sulfated polysaccharide, inhibits osteoclast differentiation and function by modulating RANKL signaling", Int. J. Mol. Sci, 15, pp.18840~18855 (2014)
- 김범수, "Fucoidan promotes osteoblast differentiation via JNK- and ERK-dependent BMP2–Smad 1", 5, Experimental and Molecular Medicine, pp.2015, 47[DOI]
- Jin X, "Low-molecular weight fucoidan inhibits the differentiation of osteoclasts and reduces osteoporosis in ovariectomized rats", Mol. Med. Rep, 15, pp.890~898 (2017)
- Lu SH, "Fucoidan prevents RANKL-stimulated osteoclastogenesis and LPS-induced inflammatory bone loss via regulation of Akt", GSK3beta, NFATc1 signaling pathway and calcineurin activity, pp.Mar. Drugs, 2019[DOI]
- Park SJ, "The sulfated polysaccharide fucoidan stimulates osteogenic differentiation of human adiposederived stem cells", Stem Cells Dev, 21, pp.2204~2211 (2011)
- Cho YS, "Beneficial effects of fucoidan on osteoblastic MG-63 cell differentiation", Food Chem, 116, pp.990~994 (2009)
- 이유경, "Variation in Fucoidan Contents and Monosaccharide Compositions of KoreanUndaria pinnatifida (Harvey) Suringar (Phaeophyta)", ALGAE, 21(1), pp.157~160 (2006), 한국조류학회I
- Ahmed Zayed, "Fucoidan Characterization: Determination of Purity and Physicochemical and Chemical Properties", Marine Drugs, 18(11), pp.571~ (2020), MDPI AG[DOI]
- van Weelden G, "Fucoidan structure and activity in relation to anti-cancer mechanisms", Mar. Drugs, 17, pp.32~ (2019)
- Mansour MB, "Primary structure and anticoagulant activity of fucoidan from the sea cucumber Holothuria polii", Int. J. Biol. Macromol, 121, pp.1145~1153 (2019)
- Min SK, "An antithrombotic fucoidan, unlike heparin, does not prolong bleeding time in a murine arterial thrombosis model : a comparative study of Undaria pinnatifida sporophylls and Fucus vesiculosus", Phytother. Res, 26, pp.752~757 (2012)
- Apostolov E, "Immunomodulatory and anti-inflammatory effects of fucoidan : a review", Polymers(Basel), 12, pp.2338~ (2020)
- Wang W, "Inhibition of influenza a virus infection by fucoidan targeting viral neuraminidase and cellular EGFR pathway", Sci. Rep, 7, pp.40760~ (2017)
- Wang Y, "Biological activities of fucoidan and the factors mediating its therapeutic effects : a review of recent studies", Mar. Drugs, 2019, pp.17~ (2019)[DOI]
- Yang JY, "Fucoidans and bowel health", Mar. Drugs, 19, pp.436~ (2019)
- Wang X, "Anti-metabolic syndrome effects of fucoidan from Fucus vesiculosus via reactive oxygen species-mediated regulation of JNK, Akt, and AMPK signaling", Molecules, 24, pp.3319~ (2019)
- Wu SY, "Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR", STAT3, Clin. Transl. Med, pp.2020, 10[DOI]
- Wang J, "Potential antioxidant and anticoagulant capacity of low molecular weight fucoidan fractions extracted from Laminaria japonica", Int. J. Biol. Macromol, 46, pp.6~12 (2010)
- Zhao X, "Antithrombotic activity of oral administered low molecular weight fucoidan from Laminaria japonica", Thromb. Res, 144, pp.46~52 (2016)
- Cui W, "Low-molecular-weight fucoidan protects endothelial function and ameliorates basal hypertension in diabetic Goto-Kakizaki rats", Lab. Invest, 94, pp.382~393 (2014)
- Madeira JV, "Biotransformation and bioconversion of phenolic compounds obtainment : an overview", Crit. Rev. Biotechnol, 35, pp.75~81 (2015)
- Singh R, "Microbial biotransformation : a process for chemical alterations", J. Bacteriol. Mycol, 4, pp.85~ (2017)
- Kee SH, "Bioconversion of agro-industry sourced biowaste into biomaterials via microbial factories-A viable domain of circular economy", Environ. Pollut, 271, pp.116311~ (2021)
- Li B, "Fucoidan : structure and bioactivity", Molecules, 13, pp.1671~1695 (2008)
- Morya VK, "Algal fucoidan : structural and size-dependent bioactivities and their perspectives", Appl. Microbiol. Biotechnol, 93, pp.71~82 (2012)
- Ale MT, "Important determinants for fucoidan bioactivity : a critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds", Mar. Drugs, 9, pp.2106~2130 (2011)
- So H, "Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression", J. Biolog. Chem, 278, pp.24209~24216 (2003)
- Rethineswaran VK, "Enzyme-aided extraction of fucoidan by AMG augments the functionality of EPCs through regulation of the AKT", Rheb signaling pathway, 2019, pp.17, 392~
- Lee JW, "Ribavirin enhances osteoclast formation through osteoblasts via upregulation of TRANCE", RANKL, 2007, pp.296, 17~24